Navigation Links
Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Date:1/3/2012

46% reduction in breast cancer recurrence in low HER2 expressing tumors together with excellent safety enables us to move forward in requesting an End-of-Phase II meeting with the FDA."

Importantly, the majority of women with loco-regional breast cancer have low to moderate expressing HER2 tumors and currently are treated with chemotherapy and radiotherapy only. There is no approved targeted HER2 therapy for these women.

"We are excited and committed to move the AE37 cancer vaccine through the appropriate scientific and regulatory steps," commented Mark Fletcher, President & Chief Executive Officer of Generex.  "AE37 not only continues to move closer to market approval but also provides validation for the underlying Ii-Key technology platform upon which it is based."

Phase I studies clearly identified the potential for AE37 to induce the immune system to focus on the HER2 protein through helper (CD4) and cytotoxic (CD8) immune cells in patients.  The HER2 protein is expressed on a high percentage of cancers in the breast, prostate, ovaries, gastro-intestinal tract, and lung.  In two Phase I trials, AE37 has demonstrated a good safety profile in both breast and prostate cancer patients.

The AE37 cancer vaccine has also completed a Phase 1 trial in prostate cancer demonstrating appropriate dosing and immune activation similar to that seen in the breast cancer trials.  The Phase 2b breast trial results add to AE37's database on tolerability and safety and have raised the possibility of using AE37 early in prostate cancer therapy.  With the Phase 2b breast cancer trial suggesting immune activation by AE37 could control breast cancer and seeing similar immune activation in the Phase I prostate trial, the Company is encouraged to move AE37 cancer vaccine more rapidly into larger clinical trials in men with newly diagnosed HER2 positive prostate cancer.  These Phase 2 trials are being designed with leading onc
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
5. Generex Provides Update on Spinout of Antigen Express
6. Generex Augments Cash Position With Sales of Non-Essential Assets
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
9. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
10. Generex Provides Clarification of Facts
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Jan. 31 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... criteria to proceed to full enrolment in its ... of REOLYSIN(R) in patients with,various sarcomas that have ... trial protocol, to proceed to full enrolment of ...
... blueprint of all life, giving instruction and function to ... beings. Now Northwestern University researchers report they have used ... build a three-dimensional structure out of gold, a lifeless ... the researchers built two common but very different crystalline ...
... 19.8% Revenue Growth -, PRINCETON, N.J., Jan. 30 ... fourth quarter ended December 31, 2007,of $0.78 per diluted ... $0.06 per share gain from the sale of its ... $0.72 per diluted share in the,fourth quarter, representing 21.8% ...
Cached Biology Technology:Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial 2Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial 3DNA is blueprint, contractor and construction worker for new structures 2DNA is blueprint, contractor and construction worker for new structures 3Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 2Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 3Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 4Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 5Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 6Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 7Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 8Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 9Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 10Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 11
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/15/2014)... NEW YORK , Nov. 13, 2014  While we ... of technology Doctor McCoy used in "Star Trek" to gain ... and tools designed to work with smartphones and tablets for ... corners of the healthcare world. This may seem a tad ... are ready to adopt some of these technological opportunities into ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... using a novel technique to better understand mineral growth ... Ridge National Laboratory are improving predictions of mineral reactions ... oil pipes clear to sequestering radium. The mineral ... generally, but also because it is the dominant scale-forming ...
... SUNY Downstate Medical Center,s growth into a major center ... awarded SUNY Downstate a four-year challenge grant of $220,000 ... causes, treatment, and prevention of blinding diseases. Douglas R. ... principal investigator. RPB is the world,s leading voluntary organization ...
... one of the most common neurological diseases, more than 4,000 ... decoded over the next five years in a study led ... and several collaborating institutions. Daniel Lowenstein, MD , ... been attempted for identifying the genetic causes of epilepsy, and ...
Cached Biology News:Metadynamics technique offers insight into mineral growth and dissolution 2SUNY Downstate receives grant from research to prevent blindness 2UCSF shares $25-million grant to find epilepsy genes 2UCSF shares $25-million grant to find epilepsy genes 3
... system, 220-240 V, is used for nucleic acid ... slab gel format. The system includes the modular ... separating nucleic acids with single base-pair resolution and ... and bonded inner glass plate, outer glass plate, ...
... PowerPac HV high-voltage power supply, with temperature probe, ... of 5,000 V, 500 mA, and 400 W. ... temperature between 0 and 90 degrees C during ... transfer. Power cord and instructions are provided. Dimensions ...
... cooling coil, Trans-Blot cell, provides ... high-intensity, and extended electrophoretic transfer ... Trans-Blot cell. Use of the ... to an external water recirculator, ...
... By incorporating a wide range of next-generation ... sets a new standard for flexible laboratory ... handling including pipetting, dilution, dispensing, and ... thats as powerful and flexible as it ...
Biology Products: